Pharmacokinetic variability of quetiapine and the active metabolite n-desalkylquetiapine in psychiatric patients

Therapeutic Drug Monitoring

Volumn 33, Issue 2, 2011, Pages 222-226

  Bakken, Gry Vibeke ^a   Rudberg, Ida ^a   Molden, Espen ^a,b   Refsum, Helge ^a   Hermann, Monica ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

N desalkylquetiapine; pharmacokinetics; quetiapine; therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; DRUG METABOLITE; N DESALKYLQUETIAPINE; PHENOBARBITAL; QUETIAPINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL;

AGE FACTORS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CYTOCHROME P-450 CYP3A; DIBENZOTHIAZEPINES; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; TIME FACTORS;

EID: 79953170187     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31821160c4     Document Type: Article

References (20)

1. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression-a double-blind, placebocontrolled study (The BOLDER II study). J Clin Psychopharmacol. 2006; 26:600-609. (Pubitemid 44772737)
2. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351-1360. (Pubitemid 40905587)
3. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13: 917-932.
4. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70:540-549.
5. Seroquel prescribing information. Available at: http://www.seroquelxr. com. Accessed October 20, 2010.
6. Grimm SW, Stams KR, Bui K. In vitro prediction of potential metabolic drug interactions for Seroquel. Schizophr Res. 1997;24:198.
7. Bakken GV, Rudberg I, Christensen H, et al. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B-5. Drug Metab Dispos. 2009;37:254-258.
8. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509-522.
9. Jensen NH, Rodriguiz RM, Caron MG, et al. N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33:2303-2312.
10. http://www.cyp450.no Accessed November 21, 2008.
11. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine; 2007. Available at: http:// medicine.iupui.edu/clinpharm/ddis/table.asp. Accessed November 21, 2008.
12. Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry. 2007;68:1540-1545. (Pubitemid 350073402)
13. Schmucker DL. Liver function and phase I drug metabolism in the elderly-a paradox. Drugs Aging. 2001;18:837-851. (Pubitemid 34073129)
14. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67-76.
15. Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients-the influence of comedication. Ther Drug Monit. 2004;26: 486-491. (Pubitemid 39314315)
16. Seroquel prescribing information. Available at: http://www.seroquel.info. Accessed September 9, 2010.
17. Wong EHF, Sonders MS, Amara SG, et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry. 2000;47:818-829. (Pubitemid 30254055)
18. Brunello N, Mendlewicz J, Kasper S, et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol. 2002;12:461-475.
19. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53:193-203. (Pubitemid 36135929)
20. Grimm SW, Richtand NM, Winter HR, et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61:58-69. (Pubitemid 43381238)